文献速递心力衰竭与心肌病

心力衰竭药物治疗对标准化肾脏结局的效应:6项随机临床试验的个体参与者水平综合分析

Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials.
PubMed 文献 · Circulation · 2024-09-01

该研究基于6项心衰试验的个体数据,用统一标准(eGFR持续下降40%、50%或57%,终末期肾病或肾性死亡)评估甾体类盐皮质激素受体拮抗剂、沙库巴曲缬沙坦和SGLT2抑制剂对复合肾脏结局的影响。应用标准化严格肾脏终点定义时,三类药物对肾脏结局为中性或有益效应。

要点

  • 统一严格肾脏终点定义下,三类心衰药物对肾脏结局为中性或有益。
  • 甾体类MRA在宽松定义下增加复合肾脏终点风险,严格定义下不再显著。
  • 沙库巴曲缬沙坦在不同eGFR阈值下均一致降低复合肾脏终点。

核心结论

  • 应用标准化严格肾脏终点定义时,甾体类MRA、沙库巴曲缬沙坦和SGLT2抑制剂对心衰患者肾脏结局具有中性或有益效应。
  • 采用较宽松定义会增加事件率,但可能纳入未必反映肾病进展长期效应的eGFR急性下降。

研究设计与样本

  • 个体参与者水平分析,纳入6项当代心衰随机临床试验:EMPHASIS-HF、TOPCAT Americas、PARADIGM-HF、PARAGON-HF、DAPA-HF和DELIVER。
  • 标准化复合肾脏终点定义为eGFR持续下降40%、50%或57%(后续至少30天确认)、终末期肾病或肾性死亡。
  • eGFR采用2009年CKD-EPI肌酐方程标准化重新计算。

主要发现

  • 采用严格定义(eGFR下降57%)时,复合肾脏终点发生比例为0.3%-3.3%;采用较宽松定义(eGFR下降40%)时为1.0%-10.0%。
  • 甾体类MRA在 least stringent 定义下使复合肾脏终点风险加倍(与安慰剂相比),但更严格定义下效应减弱且不再显著。
  • 沙库巴曲缬沙坦在不同eGFR阈值下均一致降低复合肾脏终点发生。
  • SGLT2抑制剂在更严格eGFR阈值下对复合肾脏终点的潜在获益更明显,但各效应均未达统计学显著。

临床怎么用

  • 解读心衰试验肾脏结局时需注意复合终点定义的严格程度,避免将宽松定义下的eGFR急性下降误判为长期肾损害。
  • 甾体类MRA在宽松肾脏定义下显示的风险信号在严格定义下未持续,临床决策应结合具体终点定义。
  • 沙库巴曲缬沙坦在不同eGFR阈值下均显示一致肾脏获益趋势,支持其肾脏安全性。
  • SGLT2抑制剂的肾脏获益在更严格eGFR阈值下更明显,但需更多证据确认统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney outcomes have been variably defined using nonstandardized composite end points in key heart failure trials, thus introducing complexity in their interpretation and cross-trial comparability. We examined the effects of steroidal mineralocorticoid receptor antagonists, the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan, and SGLT2 (sodium-glucose cotransporter-2) inhibitors on composite kidney end points using uniform definitions in 6 contemporary heart failure trials. METHODS: Individual participant-level data from trials of steroidal mineralocorticoid receptor antagonists (EMPHASIS-HF [Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure], TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist] Americas), angiotensin receptor-neprilysin inhibitor (PARADIGM-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure], PARAGON-HF [Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blockers Global Outcomes in HF With Preserved Ejection Fraction]), and SGLT2 inhibitors (DAPA-HF [Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure], DELIVER [Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure]) were included. The standardized composite kidney end point was defined as a sustained decline (a reduction in estimated glomerular filtration rate (eGFR) confirmed by a subsequent measurement at least 30 days later) in eGFR by 40%, 50%, or 57%; end-stage kidney disease; or renal death. eGFR was recalculated in a standardized manner using the 2009 Chronic Kidney Disease Epidemiology Collaboration creatinine equation. RESULTS: Among 28 690 participants across the 6 trials (median age, 69 years [interquartile range, 62-76]; 9656 [33.7%] women), the proportion experiencing the composite kidney end point with a more stringent definition of a sustained decline in kidney function (eGFR threshold of 57%) ranged from 0.3% to 3.3%. The proportion of patients experiencing this end point with a less stringent definition (eGFR threshold of 40%) ranged from 1.0% to 10.0%. The steroidal mineralocorticoid receptor antagonists doubled the risk of the composite kidney end point when applying the least stringent definition compared with placebo, but these effects were less apparent and no longer significant with application of more stringent definitions. Angiotensin receptor-neprilysin inhibitor appeared to consistently reduce the occurrence of the composite kidney end points irrespective of the specific eGFR threshold applied. The potential benefits of SGLT2 inhibitors on the composite kidney end points appeared more apparent when defined by more stringent eGFR thresholds, although none of these effects individually were statistically significant. CONCLUSIONS: When applying standardized stringent kidney end point definitions, steroidal mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and SGLT2 inhibitors have either neutral or beneficial effects on kidney outcomes in heart failure. Applying less stringent definitions increased event rates but included acute declines in eGFR that might not ultimately reflect long-term effects on kidney disease progression.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Butt JH, McMurray JJV, Claggett BL, et al. Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical Trials. Circulation. 2024. PMID: 39217458. doi:10.1161/CIRCULATIONAHA.124.071110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。